HIV

The ruling of Braidwood Management v Becerra puts HIV pre-exposure prophylaxis (PrEP) coverage at risk, potentially leading to more than 2000 preventable HIV infections in the coming year.

Panelists provide their closing thoughts on the disease state and treatment landscape of multidrug-resistant HIV.

Dr Lopes and Mr Driffin discuss cost considerations and utilization barriers inhibiting treatment for patients with multidrug-resistant HIV.

Maria Lopes, MD, MS, and Mr Driffin explore total cost of care affected by various multidrug-resistant treatment regimens.

Similar to findings among young adults, children with HIV in Tanzania were found to have lower distortion product otoacoustic emissions (DPOAEs) and auditory brainstem responses (ABR) wave V amplitudes, compared with children without HIV.

The patient, referred to as the “New York patient,” was treated with stem cells from cord blood, and has remained HIV-free in her blood since her transplant in 2017.

Daniel Driffin, BS, MPH, provides insights regarding factors influencing patient adherence to multidrug-resistant HIV treatment.

Dr Sension underlines the value of CD4 recovery from payer and clinician perspectives.

Study results indicates that the injectable antiretroviral therapy can benefit patients who are historically underserved and may face treatment barriers, including those with mental illness.

Since 2004, the number of individuals with HIV receiving antiretroviral therapy (ART) has increased 300-fold through the US President’s Emergency Plan for AIDS Relief (PEPFAR).

Key opinion leaders highlight barriers to MDR HIV treatment adherence.

The panel discusses considerations for payers as well as patient adherence to treatment in MDR HIV.

Body mass index and nadir CD4 count were major factors in SARS-CoV-2 humoral immune repertoire among people with HIV.

Researchers found that only 8 of 18 HIV risk assessment models have been externally validated and show moderate-to-good discrimination ability for HIV infection prediction.

Therapy adjustments in MDR HIV are explored by Dr Sension.

Optimized background regimens are highlighted in the treatment approach for MDR HIV by Michael Sension, MD.

The study also showed, despite an existing association between discrimination based on sexual orientation and HIV pre-exposure prophylaxis (PrEP) use, increased resilience reduced the effects of such discrimination on PrEP use.

The 3 companies announced a partnership to provide free, same-day prescription delivery of HIV pre-exposure prophylaxis (PrEP) and antiretroviral medications.

Dr Haumschild leads a discussion highlighting goals of therapy and social determinants of health affecting MDR HIV diagnosis and treatment.

A panel of experts explore burdens impacting patients diagnosed with MDR HIV.

A global case series described a severe form of mpox linked to a 15% mortality rate among people living with HIV and low CD4 counts.

Michael Sension, MD, provides insights on resistance mechanisms promoting MDR HIV.

Ryan Haumschild, PharmD, MS, MBA, opens a panel discussion surrounding the incidence and prevalence of multidrug-resistant (MDR) HIV.

A fifth person has been cured of HIV following a stem cell transplant for cancer; a new study examining a treatment of spinal cord stimulation after stroke had favorable results; some food companies enraged by proposed FDA healthy food guidelines.

An HIV prevention and treatment program implemented in Zambian criminal justice facilities demonstrated high levels of pre-exposure prophylaxis (PrEP) uptake among at-risk individuals.